Comment on "Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis"

Actas Dermosifiliogr. 2017 Sep;108(7):695-696. doi: 10.1016/j.ad.2017.03.012. Epub 2017 May 11.

[Article in English, Spanish]

Authors

J M P A van den Reek¹, W Kievit², E M G J de Jong³

Affiliations

¹ Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Juul.vandenReek@Radboudumc.nl.
² Department of Health Evidence, Radboud Institute of Health Sciences, Nijmegen, The Netherlands.
³ Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands; Radboud University, Nijmegen, The Netherlands.

PMID: 28504083
DOI: 10.1016/j.ad.2017.03.012

No abstract available

Publication types

Letter
Comment

MeSH terms

Dermatologic Agents
Drug Therapy, Combination*
Humans
Psoriasis*
Survival Analysis
Treatment Outcome

Substances

Dermatologic Agents